留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝癌肝移植术后复发转移的防治策略和靶向免疫治疗

秦小琰, 刘彦尧, 康权. 肝癌肝移植术后复发转移的防治策略和靶向免疫治疗[J]. 器官移植, 2022, 13(2): 271-276. doi: 10.3969/j.issn.1674-7445.2022.02.018
引用本文: 秦小琰, 刘彦尧, 康权. 肝癌肝移植术后复发转移的防治策略和靶向免疫治疗[J]. 器官移植, 2022, 13(2): 271-276. doi: 10.3969/j.issn.1674-7445.2022.02.018
Qin Xiaoyan, Liu Yanyao, Kang Quan. Prevention and therapeutic strategies and targeted immunotherapy for hepatocellular carcinoma recurrence and metastasis after liver transplantation[J]. ORGAN TRANSPLANTATION, 2022, 13(2): 271-276. doi: 10.3969/j.issn.1674-7445.2022.02.018
Citation: Qin Xiaoyan, Liu Yanyao, Kang Quan. Prevention and therapeutic strategies and targeted immunotherapy for hepatocellular carcinoma recurrence and metastasis after liver transplantation[J]. ORGAN TRANSPLANTATION, 2022, 13(2): 271-276. doi: 10.3969/j.issn.1674-7445.2022.02.018

肝癌肝移植术后复发转移的防治策略和靶向免疫治疗

doi: 10.3969/j.issn.1674-7445.2022.02.018
基金项目: 

重庆市卫生计生委医学科研计划项目 2017MSXM041

详细信息
    作者简介:
    通讯作者:

    康权,男,1973年生,硕士研究生导师,主任医师,研究方向为肝移植、肿瘤发病机制及基因治疗、儿童普通外科疾病,Email:564799351@qq.com

  • 中图分类号: R617, R753.7

Prevention and therapeutic strategies and targeted immunotherapy for hepatocellular carcinoma recurrence and metastasis after liver transplantation

More Information
  • 摘要: 随着肝移植技术的发展和成熟,肝移植已成为治疗肝细胞癌(肝癌)的重要治疗手段之一,术后肿瘤复发转移是影响受者长期生存的重要原因之一,研究肝癌肝移植术后肿瘤复发转移的防治策略是提高肝癌肝移植受者临床疗效的关键。对肝癌肝移植受者肿瘤复发转移进行密切监测、积极预防、早期诊断,综合手术治疗、局部治疗特别是靶向免疫治疗等在内的多种治疗方式,制定术后个体化防治策略,对于肝癌肝移植术后肿瘤复发转移的防治具有重要意义。本文对肝癌肝移植术后肿瘤复发转移的监测、诊断、预防和治疗进行综述,以期为肝移植受者术后肿瘤复发转移的防治提供参考,提高临床肝移植疗效,改善受者生存质量。

     

  • [1] SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
    [2] 梁军, 李丽. 肝癌免疫治疗策略的进展与思考[J]. 中华消化外科杂志, 2021, 20(2): 184-190. DOI: 10.3760/cma.j.cn115610-20201228-00809.

    LIANG J, LI L. Progress and consideration of immunotherapy strategy for hepatocellular carcinoma[J]. Chin J Dig Surg, 2021, 20(2): 184-190. DOI: 10.3760/cma.j.cn115610-20201228-00809.
    [3] YOH T, SEO S, TAURA K, et al. Surgery for recurrent hepatocellular carcinoma: achieving long-term survival[J]. Ann Surg, 2021, 273(4): 792-799. DOI: 10.1097/SLA.0000000000003358.
    [4] SAPISOCHIN G, BRUIX J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(4): 203-217. DOI: 10.1038/nrgastro.2016.193.
    [5] 中国医师协会器官移植医师分会, 中华医学会器官移植学分会. 中国肝癌肝移植临床实践指南(2018版)[J]. 临床肝胆病杂志, 2019, 35(2): 275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008.

    Branch of Organ Transplant Physician of Chinese Medical Doctor Association, Branch of Organ Transplantation of Chinese Medical Association. The Chinese clinical practice guideline on liver transplantation for hepatocellular carcinoma (2018)[J]. J Clin Hepatol, 2019, 35(2): 275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008.
    [6] RUDNICK SR, RUSSO MW. Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(3): 265-275. DOI: 10.1080/17474124.2018.1417035.
    [7] 刘召波, 栗光明. 肝移植术后肝癌复发防治进展[J]. 临床肝胆病杂志, 2021, 37(2): 267-271. DOI: 10.3969/j.issn.1001-5256.2021.02.006.

    LIU ZB, LI GM. Advances in the prevention and treatment of hepatocellular carcinoma recurrence after liver transplantation[J]. J Clin Hepatol, 2021, 37(2): 267-271. DOI: 10.3969/j.issn.1001-5256.2021.02.006.
    [8] 刘少儒, 许磊波. 肝癌肝移植术后复发转移的免疫治疗[J]. 器官移植, 2021, 12(3): 272-279. DOI: 10.3969/j.issn.1674-7445.2021.03.004.

    LIU SR, XU LB. Immunotherapy of recurrence and metastasis after liver transplantation for liver cancer[J]. Organ Transplant, 2021, 12(3): 272-279. DOI: 10.3969/j.issn.1674-7445.2021.03.004.
    [9] KIM JM. Can hepatocellular carcinoma recurrence be prevented after liver transplantation?[J]. Clin Mol Hepatol, 2021, 27(4): 562-563. DOI: 10.3350/cmh.2021.0276.
    [10] SATAPATHY SK, DAS K, KOCAK M, et al. No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant[J]. Clin Transplant, 2018, 32(5): e13246. DOI: 10.1111/ctr.13246.
    [11] GIAKOUSTIDIS AE, GIAKOUSTIDIS DE. Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma[J]. Immunotherapy, 2017, 9(2): 197-206. DOI: 10.2217/imt-2016-0110.
    [12] 中华医学会器官移植学分会. 中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019版)[J]. 器官移植, 2021, 12(1): 8-14, 28. DOI: 10.3969/j.issn.1674-7445.2021.01.002.

    Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)[J]. Organ Transplant, 2021, 12(1): 8-14, 28. DOI: 10.3969/j.issn.1674-7445.2021.01.002.
    [13] FOERSTER F, HOPPE-LOTICHIUS M, VOLLMAR J, et al. Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre[J]. United European Gastroenterol J, 2019, 7(6): 838-849. DOI: 10.1177/2050640619840221.
    [14] European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
    [15] 郑树森, 程启阳, 耿磊, 等. 肝癌肝移植术后肝癌复发研究新进展[J]. 中国普通外科杂志, 2019, 28(7): 773-778. DOI: 10.7659/j.issn.1005-6947.2019.07.001.

    ZHENG SS, CHENG QY, GENG L, et al. Tumor recurrence after liver transplantation for hepatocellular carcinoma: recent research progress[J]. Chin J Gen Surg, 2019, 28(7): 773-778. DOI: 10.7659/j.issn.1005-6947.2019.07.001.
    [16] LI M, WANG Z, CAO J, et al. Risk factors and prognosis of patients with recurrent hepatocellular carcinoma who undergo liver re-resections[J]. Eur J Surg Oncol, 2019, 45(9): 1684-1690. DOI: 10.1016/j.ejso.2019.04.008.
    [17] FERNANDEZ-SEVILLA E, ALLARD MA, SELTEN J, et al. Recurrence of hepatocellular carcinoma after liver transplantation: is there a place for resection?[J]. Liver Transpl, 2017, 23(4): 440-447. DOI: 10.1002/lt.24742.
    [18] ROAYAIE S, BASSI D, TARCHI P, et al. Second hepatic resection for recurrent hepatocellular cancer: a Western experience[J]. J Hepatol, 2011, 55(2): 346-350. DOI: 10.1016/j.jhep.2010.11.026.
    [19] YAMASHITA Y, SHIRABE K, TSUIJITA E, et al. Third or more repeat hepatectomy for recurrent hepatocellular carcinoma[J]. Surgery, 2013, 154(5): 1038-1045. DOI: 10.1016/j.surg.2013.04.046.
    [20] BALE R, SCHULLIAN P, EBERLE G, et al. Stereotactic radiofrequency ablation of hepatocellular carcinoma: a histopathological study in explanted livers[J]. Hepatology, 2019, 70(3): 840-850. DOI: 10.1002/hep.30406.
    [21] OLIGANE HC, XING M, KIM HS. Effect of bridging local-regional therapy on recurrence of hepatocellular carcinoma and survival after orthotopic liver transplantation[J]. Radiology, 2017, 282(3): 869-879. DOI: 10.1148/radiol.2016160288.
    [22] SAPISOCHIN G, GOLDARACENA N, ASTETE S, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series[J]. Ann Surg Oncol, 2015, 22(7): 2286-2294. DOI: 10.1245/s10434-014-4273-6.
    [23] INVERNIZZI F, IAVARONE M, CZAUDERNA C, et al. Safety and effectiveness of regorafenib in recurrent HCC after liver transplantation and progression on sorafenib: a real-life multicentre study[J]. Digest Liver Dis, 2019, 51(Suppl 1): e12. DOI: 10.1016/j.dld.2018.11.058.
    [24] KWONG A, KIM WR, LAKE JR, et al. OPTN/SRTR 2018 annual data report: liver[J]. Am J Transplant, 2020, 20(Suppl s1): 193-299. DOI: 10.1111/ajt.15674.
    [25] VIVARELLI M, CUCCHETTI A, PISCAGLIA F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression[J]. Liver Transpl, 2005, 11(5): 497-503. DOI: 10.1002/lt.20391.
    [26] VIVARELLI M, CUCCHETTI A, LA BARBA G, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence[J]. Ann Surg, 2008, 248(5): 857-862. DOI: 10.1097/SLA.0b013e3181896278.
    [27] JUNG DH, TAK E, HWANG S, et al. Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence[J]. Liver Transpl, 2018, 24(7): 932-945. DOI: 10.1002/lt.25191.
    [28] INVERNIZZI F, IAVARONE M, ZAVAGLIA C, et al. Experience with early sorafenib treatment with mTOR inhibitors in hepatocellular carcinoma recurring after liver transplantation[J]. Transplantation, 2020, 104(3): 568-574. DOI: 10.1097/TP.0000000000002955.
    [29] YANIK EL, CHINNAKOTLA S, GUSTAFSON SK, et al. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma[J]. Liver Transpl, 2016, 22(5): 627-634. DOI: 10.1002/lt.24395.
    [30] 贺强, 周林. 构建以雷帕霉素为主预防肝癌肝移植术后肿瘤复发的综合防治体系[J/CD]. 肝癌电子杂志, 2021, 9(3): 1-7. DOI: 10.3969/j.issn.2095-7815.2021.03.001.

    HE Q, ZHOU L. To establish a comprehensive prevention and treatment system based on rapamycin for cancer recurrence after liver transplantation[J/CD]. Electr J Liver Tumor, 2021, 9(3): 1-7. DOI: 10.3969/j.issn.2095-7815.2021.03.001.
    [31] ABDEL-WAHAB N, SAFA H, ABUDAYYEH A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature[J]. J Immunother Cancer, 2019, 7(1): 106. DOI: 10.1186/s40425-019-0585-1.
    [32] 施国明, 黄晓勇, 任正刚, 等. 肝癌免疫检查点抑制剂相关不良反应管理中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(12): 1241-1258. DOI: 10.3760/cma.j.cn115610-20211125-00594.

    SHI GM, HUANG XY, REN ZG, et al. Chinese expert consensus on the management of immune-related adverse events of hepatocellular carcinoma treated with immune checkpoint inhibitors (2021 edition)[J]. Chin J Dig Surg, 2021, 20(12): 1241-1258. DOI: 10.3760/cma.j.cn115610-20211125-00594.
    [33] SABERIANFAR S, NGUYEN LS, MANOUCHEHRI A, et al. Solid organ transplant rejection associated with immune-checkpoint inhibitors[J]. Ann Oncol, 2020, 31(4): 543-544. DOI: 10.1016/j.annonc.2020.01.012.
    [34] HO CM, CHEN HL, HU RH, et al. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective[J]. Ther Adv Med Oncol, 2019, 11: 1758835919843463. DOI: 10.1177/1758835919843463.
    [35] DELEON TT, SALOMAO MA, AQEL BA, et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience[J]. J Gastrointest Oncol, 2018, 9(6): 1054-1062. DOI: 10.21037/jgo.2018.07.05.
  • 加载中
图(1)
计量
  • 文章访问数:  1273
  • HTML全文浏览量:  386
  • PDF下载量:  262
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-11-03
  • 网络出版日期:  2022-03-18
  • 刊出日期:  2022-03-15

目录

    /

    返回文章
    返回